NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview.

Pramono, Alvinsyah Adhityo; Rather, Gulam M; Herman, Herry; Lestari, Keri; Bertino, Joseph R

Pramono, Alvinsyah Adhityo; Rather, Gulam M; Herman, Herry; Lestari, Keri; Bertino, Joseph R.

Afiliação

Pramono AA; Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA.
Rather GM; Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia.
Herman H; Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Sumedang 45363, Indonesia.
Lestari K; Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA.
Bertino JR; Division of Oncology, Department of Orthopaedic Surgery, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia.

Biomolecules ; 10(3)2020 02 26.

Article em En | MEDLINE | ID: mdl-32111066

Assuntos

Antineoplásicos/farmacologia; Vias Biossintéticas/efeitos dos fármacos; Descoberta de Drogas; NADP/metabolismo; NAD/metabolismo; Neoplasias/enzimologia; Animais; Inibidores Enzimáticos/farmacologia; Humanos; Terapia de Alvo Molecular; Neoplasias/tratamento farmacológico; Neoplasias/metabolismo; Nicotinamida Fosforribosiltransferase/antagonistas & inibidores; Nicotinamida Fosforribosiltransferase/metabolismo

Palavras-chave

IDH mutation; NAD/NADPH pool; NADK inhibitor; NAMPT inhibitor; dihydrofolate reductase

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vias Biossintéticas / Descoberta de Drogas / NAD / NADP / Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google